Clinical trial
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic…
NCT04158362 · UNICANCER, Other · Active, not recruiting
Key facts
| NCT number | NCT04158362 |
|---|---|
| Title | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer |
| Official title | Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease |
| Acronym | AMBRE |
| Lead sponsor | UNICANCER, Other |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer Metastatic |
| Intervention type | Drug |
| Interventions | Paclitaxel injection, Capecitabine tablets, Letrozole 2.5mg, Anastrozole 1mg, Fulvestrant Prefilled Syringe, Abemaciclib |
| Enrollment | 180 |
| Start date | Jun 11, 2020 |
| Primary completion | Apr 30, 2025 |
| Completion | Jun 1, 2028 |
| First posted | Nov 8, 2019 |
| Last update posted | Sep 22, 2025 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: